FOI2026/00106 – Specific adverse event report
Published 20 March 2026
© Crown copyright 2026
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/vmd-foieir-requests-january-2026/foi202600106-specific-adverse-event-report
Your request
I am requesting all the information you hold in my name and also in relation to my dog [name redacted]
Our reply
We have conducted searches across our systems and can confirm that we do not hold any record of an adverse event reported by you or relating to your dog.
Adverse events for veterinary medicines are reported directly to the Marketing Authorisation Holder (MAH). In this case, Zoetis is the MAH for the product you are referring to.
If you have experienced difficulty submitting information through their online Contact Us form, you may instead provide the details of the adverse event directly to them by email:
- Email: customersupportuk@zoetis.com
- Telephone: 0345 300 8034
- Website: https://www2.zoetis.co.uk/contact-us/
Providing the information directly will allow Zoetis to log and assess the adverse event appropriately.
You may request a copy of your adverse event report from us 30 days after submitting it to Zoetis. MAHs must report all adverse events to the VMD within 30 days of becoming aware of them, in line with paragraph 57 of the Veterinary Medicines Regulations 2013 and Guideline III on adverse event reporting.
It may be of interest to know that we are developing an advanced online adverse event reporting portal for direct reporting to the VMD. This system will integrate with existing pharmacovigilance processes to provide more comprehensive safety oversight, and an enhanced and efficient process. Full details can be found here: